Management of rectal neuroendocrine tumours by transanal endoscopic microsurgery
- PMID: 36747381
- DOI: 10.1111/codi.16506
Management of rectal neuroendocrine tumours by transanal endoscopic microsurgery
Abstract
Aim: The objective of this study was to evaluate the safety and effectiveness of transanal endoscopic microsurgery for rectal neuroendocrine tumours.
Method: A retrospective cohort study of all pathology-confirmed rectal neuroendocrine tumours treated by transanal endoscopic microsurgery from April 2007 to December 2020 at a tertiary care centre was performed. Demographic, clinical, radiographic and pathological data were collected. Characteristics of patients with recurrence were examined. Descriptive statistics were performed.
Results: There were 58 patients treated by transanal endoscopic microsurgery excision. Referrals were for primary excision (15, 25.9%), completion re-excision after incomplete endoscopic removal (38, 65.5%) or locally recurrent rectal neuroendocrine tumours (5, 8.6%). The mean age of patients was 56.4 ± 11.9 years and 26 patients were women (44.8%). Mean tumour size was 7.4 ± 3.8 mm (range 1.0-15.0 mm). Most (86.4%) were Grade 1 tumours. Mean operative time was 37.2 ± 17.2 min and 56 patients (96.6%) were discharged on the same day. All patients had negative margins on final pathology. Of the 38 patients who were referred for completion re-excision after incomplete endoscopic removal, eight (21.1%) had residual tumour on final pathology. Three recurrences were diagnosed at 2.1, 4.5 and 12.5 years after excision. All recurrences were from Grade 1 or 2 primary tumours, less than 2 cm, and diagnosed radiographically.
Conclusion: To date, this is the largest North American study looking at transanal endoscopic microsurgery for rectal neuroendocrine tumours. This technique is effective in managing primary, incompletely excised and recurrent tumours with good clinical and oncological outcomes.
Keywords: NET; TEM; neuroendocrine tumour; surgery; transanal.
© 2023 Association of Coloproctology of Great Britain and Ireland.
References
REFERENCES
-
- Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg. 2011;396(3):273-98. https://doi.org/10.1007/s00423-011-0739-1
-
- Sugimoto S, Hotta K, Shimoda T, Imai K, Yamaguchi Y, Nakajima T, et al. The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors. Surg Endosc. 2016;30(10):4239-48. https://doi.org/10.1007/s00464-015-4735-3
-
- Scherübl H. Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy. 2009;41(2):162-5. https://doi.org/10.1055/s-0028-1119456
-
- Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-59. https://doi.org/10.1002/cncr.11105
-
- Neuroendocrine and Adrenal Tumors. National Comprehensive Cancer Network (NCCN). Published December 4, 2021. Accessed October 8, 2021. https://www.nccn.org/guidelines/guidelines-detail
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous